Analysts' Actions: JNPR ADSK CMI DVN CNQR

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Autodesk ( ADSK) downgraded at Jefferies to Hold from Buy, Jefferies said. $34 price target. Weaker data and limited uplift from suites. Hold rating.

Adtran ( ADTN) upgraded at Mizuho to Buy, Mizuho said. $22 price target. Business will likely bottom out in the fourth quarter.

Cummins ( CMI) upgraded at BMO from Market Perform to Outperform, BMO Capital said. $120 price target. Global growth appears to be stabilizing.

Concur ( CNQR) downgraded at Piper from Neutral to Underweight, Piper Jaffray said. Valuation call, based on a $49 price target.

Devon Energy ( DVN) downgraded at UBS to Neutral from Buy, UBS said. $60 price target. Long term outlook dims.

Devon Energy downgraded at Citigroup. DVN was downgraded to Neutral from Buy, Citigroup said. $62 price target. Lower costs, but reining in production growth outlook.

Exelon ( EXC) upgraded at UBS to Neutral from Sell, UBS said. $30 price target. Shares now reflect a lower dvidend.

FirstMerit ( FMER) upgraded at Baird from Underperform to Neutral, Robert Baird said. Valuation call, based on a $13 price target.

Health Net ( HNT) upgraded at BMO from Underperform to Market Perform, BMO Capital said. $23 price target. Near-term visibility is improving.

Juniper ( JNPR) upgraded at Cantor from Hold to Buy, Cantor Fitzgerald said. $21 price target. Company is cutting costs and is leveraged to higher carrier spending.

Linear Technology ( LLTC) upgraded at UBS to Buy from Neutral, UBS said. $38 price target. Improved relative growth rate supports raised valuation.

Universal Display ( PANL) downgraded at Wedbush from Outperform to Neutral, Wedbush said. $20 price target. Estimates also cut, as the company has reduced visibility.

Parker Hannifin ( PH) upgraded at BMO to Outperform, BMO Capital said. Valuation call, based on a $94 price target.

Perrigo ( PRGO) downgraded at Caris from Buy to Above Average, Caris & Co. said. $129 price target. Company is seeing slower demand for consumer healthcare and nutritionals.

PSS World Medical ( PSSI) downgraded at UBS to Neutral from Buy, UBS said. $29 price target. 10Q reveals inline results.

Transocean ( RIG) upgraded at Argus from Hold to Buy, Argus said. $62 price target. Company has made several smart strategic decisions.

Rosetta Resources ( ROSE) upgraded at Citigroup to Buy from Neutral, Citigroup said. $60 price target. Solid Q3 beat and 2013 guidance.

Seattle Genetics ( SGEN) downgraded at Cantor from Hold to Sell, Cantor FItzgerald said. $20 price target. Adcetris is growing slower than expected.

STOCK COMMENTS / EPS CHANGES

Accretive Health ( AH) numbers lowered at Oppenheimer Shares of AH now seen reaching $15, Oppenheimer said. Estimates also lowered on 3Q results. Outperform rating.

Auxilium Pharma ( AUXL) numbers lowered at Jefferies. Shares of AUXL now seen reaching $29, Jefferies said. Estimates also lowered on Testim miss. Buy rating.

Cablevision ( CVC) estimates, target reduced at Morgan Stanley. Shares of CVC now seen reaching $15, according to Morgan Stanley. Estimates also cut, as the company is realizing lower margins. Underweight rating.

HollyFrontier ( HFC) numbers increased at Credit Suisse. HFC estimates were raised through 2015, Credit Suisse said. Company is seeing higher refining growth. Neutral rating and new $53 price target.

Melco Crown ( MPEL) numbers raised at Citigroup. Shares of MPEL now seen reaching $22.50, Citigroup said. Estimates also increased on Q3 beat. Buy rating.

NYSE Euronext ( NYX) numbers cut at Citigroup. Shares of NYX now seen reaching $25, Citigroup said. Estimates also lowered as environment remains challenging. Neutral rating.

RealPage ( RP) estimates, target reduced at Credit Suisse. Shares of RP now seen reaching $27, according to Credit Suisse. Estimates also cut, gvien product delays. Outperform rating.

WellPoint ( WLP) target raised at Jefferies. Shares of WLP now seen reaching $64, Jefferies said. Results show signs of stability. Hold rating.

WellPoint numbers lowered at Oppenheimer. Shares of WLP now seen reaching $73, Oppenheimer said. Estimates also lowered on 3Q results. Outperform rating.

Wellpoint estimates, target boosted at BMO. Shares of WLP now seen reaching $65, according to BMO Capital. Estimates also upped, as the company is keeping a tight lid on costs.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.